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Abstract
Background: Evidence on stages of renal impairment and related risk factors in Luxembourg is lacking. This study
aimed to assess the prevalence of chronic kidney disease (CKD) and identify potential correlates among the general
population, using the recent definition suggested by the Kidney Disease Improving Global Outcomes guidelines.
Methods: Data analysed from 1361 participants aged 18–69 years, enrolled in the Observation of Cardiovascular
Risk Factors in Luxembourg (ORISCAV-LUX) study, 2007–08. Descriptive and multivariable logistic regression analyses
were performed to identify demographic, socio-economic, behavioural, and clinical factors associated with CKD,
defined as a single estimated glomerular filtration rate (eGFR) measure <60 ml/min/1.73m2 and/or urinary albumin:
creatinine ratio (ACR) > 30 mg/g.
Results: Overall, 6.3% had CKD, including 4.4% and 0.7% with moderate and severe macroalbuminuria respectively. 0.
1% had kidney failure (eGFR < 15 ml/min/1.73 m2). CKD was higher among subjects with primary education and risk
increased significantly with age; the odd ratio was more than 2-fold higher among participants aged 50–69 years.
Hypertension and diabetes were associated with more than 3-fold and 4-fold higher risks of CKD [adjusted odd ratio
(AOR 3.46 (95%CI 1.92, 6.24), P < 0.001] and [AOR 4.45 (2.18, 9.07), P < 0.001] respectively. Increased physical activity
measured as total MET-hour/week was independently associated with a lower odds of CKD (P = 0.035).
Conclusion: The national baseline prevalence estimate of CKD, a neglected public health problem, stresses the benefit of
early detection particularly in high-risk subjects with associated cardiovascular pathologies (e.g. hypertension, diabetes), to
prevent and defray costs related to eventual complications.
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Background
During the last decade, there has been a rising interest in
the epidemiology of chronic kidney disease (CKD), which is
now recognized as an important public health problem
worldwide [1]. Patients with CKD are at high risk for
progression to end stage renal disease (ESRD); a condition
often requiring costly renal replacement therapy in the form
of dialysis or transplantation. Although over 2 million people
now require chronic renal replacement therapy worldwide
[2, 3], only a minority of patients who are at risk for
developing ESRD are under medical attention [4]. Moreover,
CKD is associated with eight- to ten-fold increased risk of
cardiovascular disease (CVD) mortality [5, 6]. Other
complications include acute kidney injury, increased risk of
infection, cognitive decline, anaemia, mineral and bone
disorders and fractures [7].
The economic impact of CKD is enormous, whether
related to direct healthcare cost or to indirect productiv-
ity lost with profound consequences on the quality of life
of the individual, his family and society [3]. Recently, the
Global Burden of Diseases, Injuries, and Risk Factors
Study (GBD) ranked low glomerular filtration rate (GFR)
as the 12th leading risk factor for death at the global
level, and the 14th risk factor for Disability-Adjusted
Life-Years (DALYs) among 79 risk factors in 2013 [8]. In
the past decade, attention has moved from treating only
advanced stages of CKD toward prevention at earlier
stages of CKD [4]. However, due to the asymptomatic
nature of slowly progressing renal damage, CKD is
frequently undetected until the very late stages, with few
opportunities for prevention. Therefore, focusing efforts
on early detection and treatment of CKD can prevent or
delay progress to kidney failure or other adverse
outcomes [9].
Low GFR has been identified among the top 10 lead-
ing cause of DALYs for both sexes in Luxembourg [10],
where cardiovascular mortality accounts for about one-
third of all deaths [11], and associated cardio metabolic
pathologies, such as diabetes, hypertension, lipid disor-
ders and obesity are demonstrably high [12, 13]. The
objectives of this study were to provide baseline evidence
on the prevalence of CKD among the general population
in Luxembourg, to assess the different stages of CKD
and identify potential socio-economic, clinical and
behavioural correlates. Accurate assessment of CKD
stages among the general population may provide
important evidence-based information for policy makers
and healthcare professionals regarding strategies for
CKD prevention and healthcare planning.
Methods
Study design and participants
Analyses were based on data from the Observation of
Cardiovascular Risk Factors in Luxembourg (ORISCAV-
LUX) survey, a nationwide population-based cross-
sectional study of adults in Luxembourg. A comprehensive
description of the study design, sampling method, sample
representativeness and data collection have been previously
reported [12, 14]. Briefly, a stratified random sample of
1432 participants, aged 18–69 years, was recruited between
November 2007 and January 2009, selected from the
national insurance registry. For the present study, data from
1359 subjects were available for analyses, as 73 (5.1%) were
excluded, because of missing blood samples to evaluate
renal function.
Data collection and measurements
Participants self-reported their health status, socioeconomic
status, personal and family medical histories and medication
use. Information concerning their lifestyle factors (cigarette
smoking, alcohol intake and physical activity) was collected
by using Fagerström Test, Alcohol Use Disorder Test
(AUDIT) and International Physical Activity Questionnaire
(IPAQ), respectively. The IPAQ allowed to calculate total
metabolic equivalent (METmin/week) for walking, moderate
and vigorous physical activities [15]. The validated semi-
quantitative FFQ [16, 17] was use to collect data on dietary
habits. Participants recorded the frequency of consumption
and portion size of 134 foods and beverages.
The clinical examination included measurements of
height, weight, and blood pressure (BP). Systolic BP and
diastolic BP (in mm Hg) were measured at least three
times with a minimum 5-min interval, by using Omrom®
MX3 plus automated oscillometric Blood Pressure
Monitor (O-HEM-742-E; Matsusaka, Japan). Participants
were classified as hypertensive when the mean of the
two last measurements was ≥140 mmHg systolic or
≥90 mmHg diastolic or when they reported taking anti-
hypertensive medications.
Height and weight were measured by using a digital
column scale (Seca 701; Hamburg Germany). BMI was
calculated as weight in kg divided by height in m2. Waist
circumference (WC, cm) was measured at the level mid-
way between the twelfth rib and the uppermost lateral
border of the iliac crest during normal expiration.
Obesity was defined as BMI ≥30 Kg/m2.
Blood samples were drawn after an overnight 8-h fast
and analysed at the national laboratory. Several parame-
ters were assessed including liver enzymes (aspartate
aminotransferase AST, alanine transaminase ALT and
gammaglutamyl transpeptidase γGT, all in mg/dl), lipids
(total cholesterol, triglycerides, high-density lipoprotein
HDL and low-density lipoprotein LDL, all in mg/dl),
glycaemic biomarkers (fasting plasma sugar FPG in mg/dl
and haemoglobin A1c in %), high sensitivity C-reactive
protein (hs-CRP; μg/l) and serum uric acid and creatinine
(Cr) concentrations in mg/dl. For the assessment of Cr, an
enzymatic method by Roche on a Cobas c501 instrument
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was used, which has calibration traceable to an isotope
dilution mass spectrometry (IDMS) reference measure-
ment procedure.
Renal function was evaluated by using estimated GFR
(eGFR), based on the widely used 4-variable Modification
of Diet in Renal Disease Study (MDRD) equation, as
follows: eGFR = 175* (serum Cr (mg/dl))-1.154 * age-0.203 *
(0.742 for women)* 1.21 if black, where GFR is expressed
as ml/min/1.73 m2 of body surface area, age in years and
serum Cr is expressed in mg/dl [1, 18]. Then, eGFR were
classified into stages 1–5, with stages 1 and 2 requiring the
presence of kidney damage such as proteinuria as well as
reduced eGFR to identify CKD [19].
Urine samples were collected as early morning, mid-
stream urine specimens. Urinary albumin was assessed
using the immunoturbidimetric assay Tinaquant
Albumin Gen. 2 by Roche Diagnostics (Mannheim,
Germany). Albumin: creatinine ratio (ACR in mg of
albumin/g of creatinine) was determined as an early
marker of glomerular injury and kidney damage.
Abnormal levels were divided into macroalbuminuria
(ACR >300 mg/g Cr) [20], which indicates advanced kid-
ney disease and microalbuminuria (ACR ≥30 mg/g and
<300 mg/g Cr) [19, 21], which indicates early-stage
kidney disease, whereas ACR level of 0–29 mg/g Cr
indicates non-clinically detected microalbuminuria.
CKD and staging
In the present study, subjects were classified as having
CKD when eGFR was <60 ml/min/1.73m2 (G3-G5), and/
or ACR >30 mg/g Cr (level A2-A3) according to the
Kidney Disease Improving Global Outcomes (KDIGO)
guidelines [22, 23].
To permit an international comparison, we also presented
the prevalence by using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) equation as follows:
GFR = 141 ×min (s-Cr /κ, 1)α ×max(s-Cr /κ, 1)-1.209 ×
0.993Age × 1.018 [if female] × 1.159 [if black] [24],
where: s-Cr is serum creatinine in mg/dl, κ is 0.7 for
females and 0.9 for males, α is −0.329 for females and
−0.411 for males, min indicates the minimum of s-Cr/κ
or 1, andmax indicates the maximum of s-Cr/κ or 1.
Statistical analysis
All statistical analyses were performed using the Statistical
Package for the Social Sciences SPSS Statistics, Inc.
version 24.0 software. Results were considered to be
significant at the 5% level (P < 0.05). Initially, the preva-
lence of different stages of CKD were estimated and
expressed as counts and proportions (%), by using both
MDRD and CKD-EPI equations. To account for the strati-
fied random sampling method, weighted statistical
methods were applied to produce nationally representative
CKD prevalence estimates. A sampling weight equal to
the inverse probability of unit selection was allocated to
each subject from the same stratum [14].
Then, descriptive analyses were performed to present
demographic, socio-economic, behavioral, and cardio
metabolic risk factors of participants with CKD, by using
MDRD equation. Univariate logistic regression analyses
were applied to identify the factors significantly associ-
ated with CKD prevalence. Results were expressed in
terms of odds ratio (OR) and the respective 95% CI. For
categorical variables, ‘low risk’ participants (younger age,
women, Luxembourgers, tertiary level of education,
living above poverty threshold, non-smokers, non-drinkers,
physically active, absence of obesity, diabetes or hyperten-
sion, and without family history of selected medical condi-
tions) were taken as reference categories.
Next, multivariable logistic regression analyses were
performed to identify the independent contribution of
socio-demographic, behavioral and biological factors to
the risk of having CKD estimated by MDRD equation.
Based on a literature review and on statistical criteria
(variables showing P < 0.05 in the univariate analyses),
the following variables were introduced in the multivari-
able model: age groups (18-49y; 50-69y), sex, education
level (primary; secondary; tertiary), BMI, WC, HDL-
cholesterol, serum triglycerides, serum ALT, hyperten-
sion (yes; no), diabetes (yes; no), and MET-hour/week
for physical activity. To take account of medication
intake, diabetes and hypertension were chosen rather
than individual biomarkers such as FPG, HbA1c, systolic
and diastolic BP. Obesity (yes; no) was not included in
the multivariable model to avoid over-adjustment [25],
likewise serum Cr as this variable is part of the eGFR
formula. Concerning race, this “mainly Europid” study is
underpowered to examine racial differences.
Results
Prevalence of CKD
Table 1 shows that 6.3% (89 participants) had CKD, where
the eGFR estimated by MDRD, including 4.4% and 0.7%
with moderate and severe albuminuria respectively, and
0.1% with kidney failure (eGFR < 15 mL/min/1.73 m2).
By using CKD-EPI equation, the prevalence estimate
was similar (5.9%; 82 subjects), with a difference of 7 cases
which were not detected via this definition (Table 2).
Factors associated with CKD
Table 3 outlines the associations between a wide-range
of demographic, behavioral and clinical characteristics of
individuals with CKD, using the MDRD definition. Over-
all, the prevalence of CKD increased significantly with
age; the odds ratio increased more than 2-fold among
subjects aged 50–69 years. The distribution of CKD
varied significantly according to education level; the
frequency of CKD was higher among subjects with
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primary education. There was no significant difference
according to geographical district or country of birth.
Among lifestyle factors, increased physical activity in
MET-hour/week was associated with slightly, but statis-
tically significantly, lower risk [odds ratio (95%CI): 0.97
(0.95, 0.99); P = 0.01)].
In univariate analyses, the prevalence of CKD differed sub-
stantially according to biochemical and clinical measure-
ments, including BMI, WC, systolic and diastolic BP, FPG,
glycated Hb, HDL-cholesterol, triglycerides and serum Cr
(all P < 0.001). Consequently, the prevalence estimates were
significantly higher in the presence of obesity, hypertension,
and diabetes and respective odd ratios were increased 3-
fold, 4-fold, and 8-fold respectively (all P < 0.001). Concern-
ing dietary intake, there were no associations of CKD with
salt, animal protein, meat, fruit or vegetable consumption.
In the multivariable analysis, increased physical activity
remained independently correlated with lower odds of
CKD [Adjusted Odds Ratio (AOR 0.97 (95%CI 0.95–0.99);
P = 0.035)]. Hypertension and diabetes were also inde-
pendently associated with more than 3-fold and 4-fold
higher risk of CKD [AOR 3.46 (1.92, 6.24); P < 0.001] and
[AOR 4.45 (2.18, 9.07); P < 0.001], respectively (Table 4).
Discussion
CKD has been recognized as a worldwide public health
problem due to rising prevalence, association with CVD
mortality, poor outcomes, and dramatic complications
which imply high costs and important burden on health
care systems [19]. Renal epidemiology has blossomed in
recent years, following several publications on renal
impairment diagnosis and uniform clinical practice
Table 1 Identification of CKD estimated by MDRD, according to levels of eGFR and ACR categories, among 1359 participants in the
Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) study, 2007-08, aged 18–69 years
eGFR and ACR categories and risk of adverse outcomes ACR categories (mg/g Cr), description and range
<30 30–300 >300
Normal to mildly increased Moderately increased Severely increased
Normoalbuminuria Microalbuminuria Macroalbuminuria
A1 A2 A3 Total
GFR categories
(ml/min/1.73 m2)
≥90 Normal and high G1 612 (48.4%) [137,188] 37 (2.8%) [7919] 5 (0.3%) [940] 654 (51.5%) [146,047]
60–89 Mild reduction G2 658 (45.3%) [128,547] 23 (1.6%) [4647] 2 (0.1%) [356] 683 (47.1%) [133,550]
30–59.9 Moderate impairment G3 17 (1.1%) [3125] 0 2 (0.1%) [348] 19 (1.2%) [3473]
15–29.9 Severe impairment G4 1 (0.1%) [194] 0 1 (0.1%) [222] 2 (0.1%) [416]
<15 Kidney failure G5 0 0 1 (0.1%) [165] 1 (0.1%) [165]
Total 1288 (94.9%) [269,054] 60 (4.4%) [12,566] 11 (0.7%) [2032] 1359 (100%) [283,652]
Data represent number (%) of participants having the pathology [Estimated population in Luxembourg]. Sample weighting used to present data
ACR albumin: creatinine ratio, CKD chronic kidney disease, GFR glomerular filtration rate
CKD identified in people with GFR <60 ml/min/1.73 m2 (GFR categories G3-G5) or markers of kidney damage. In the absence of evidence of
kidney damage such as albuminuria, neither eGFR category G1 nor G2 fulfil the criteria for CKD
Table 2 Identification of CKD estimated by CKD-EPI, according to levels of eGFR and ACR categories, among 1359 participants in
the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) study, 2007-08, aged 18–69 years
eGFR and ACR categories and risk of adverse outcomes ACR categories (mg/g Cr), description and range
<30 30–300 >300
Normal to mildly increased Moderately increased Severely increased
Normoalbuminuria Microalbuminuria Macroalbuminuria
A1 A2 A3 Total
GFR categories
(ml/min/1.73 m2)
≥90 Normal and high G1 923 (70.5%) [199,875] 48 (3.5%) [9983] 6 (0.4%) [1119] 977 (74.4%) [210,978]
60–89 Mild reduction G2 354 (23.6%) [67,172] 12 (0.9%) [2582] 1 (0.1%) [178] 367 (24.7%) [69,933]
30–59.9 Moderate impairment G3 10 (0.6%) [1812] 0 2 (0.1%) [348] 12 (0.8%) [2161]
15–29.9 Severe impairment G4 1 (0.1%) [194] 0 1 (0.1%) [222] 2 (0.1%) [416]
<15 Kidney failure G5 0 0 1 (0.1%) [165] 1 (0.1%) [165]
Total 1288 (94.9%) [269,054] 60 (4.4%) [12,566] 11 (0.7%) [2032] 1359 (100%) [283,652]
Data represent number (%) of participants having the pathology [Estimated population in Luxembourg]. Sample weighting used to present data
ACR albumin: creatinine ratio, CKD chronic kidney disease, GFR glomerular filtration rate
CKD identified in people with GFR <60 ml/min/1.73 m2 (GFR categories G3-G5) or markers of kidney damage. In the absence of evidence of
kidney damage such as albuminuria, neither eGFR category G1 nor G2 fulfil the criteria for CKD
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Table 3 Distribution of CKD according to demographic, socio-economic, behavioural and health-related characteristics of participantsa
in ORISCAV-LUX study, 2007-08, aged 18–69 years
Characteristics n No CKD CKDb Crude OR 95% CI P-value
Socio-demographic characteristics
Age (years) Mean (SD) 1359 43.8 ± 0.36 49.47 ± 1.60 1.03 (1.02–1.05) <0.001
1359 N (%) N (%)
18–49 855 (67.3) 41 (46.1) 1 (Ref.) <0.001
50–69 415 (32.7) 48 (53.9) 2.4 (1.56–3.72)
Sex 1359 0.88
Female 652 (51.3) 45 (50.6) 1(Ref.)
Male 618 (48.7) 44 (49.4) 1.03 (0.67–1.58)
Race 1359 0.42
White 1264 (99.5%) 88 (98.9%) 1(Ref.)
Black 6 (0.5%) 1 (1.1%) 0.41 (0.05–3.51)
Education level 1345 0.02
Tertiary 329 (26.2) 21 (23.6) 1(Ref.)
Secondary 599 (47.7) 33 (37.1) 0.86 (0.49–1.51)
Primary 328 (26.1) 35 (39.3) 1.67 (0.95–2.93)
Country of birth 1359 0.38
Luxembourg 762 (60) 53 (59.6) 1(Ref.)
Portugal 147 (11.6) 15 (16.9) 1.47 (0.80–2.67)
Other European countries 77 (6.1) 3 (3.4) 0.91 (0.52–1.58)
Non-European countries 284 (22.4) 18 (20.2) 0.56 (0.17–1.83)
Geographical district 1359 0.17
Luxembourg 926 (72.9) 72 (80.9) 1(Ref.)
Diekirch 190 (15) 7 (7.9) 0.47 (0.21–1.05)
Grevenmacher 154 (12.1) 10 (11.2) 0.83 (0.42–1.65)
Poverty threshold 1176 0.29
Above 236 (21.4) 19 (26.8) 1(Ref.)
Below 869 (78.6) 52 (73.2) 1.34 (0.78–2.32)
Lifestyle factors
Alcohol consumption 1359 0.22
Non-drinkers 182 (14.3) 17 (19.1) 1(Ref.)
Drinkers 1088 (85.7) 72 (80.9) 0.71 (0.41–1.23)
Smoking status 1359 0.69
Non-smokers 990 (78) 71 (79.8) 1(Ref.)
Current smokers 280 (22) 18 (20.2) 0.9 (0.53–1.53)
Total MET-hour/week, Mean (SD) 1294 13.62 (0.31) 10.58 (0.94) 0.97 (0.95–0.99) 0.01
Biochemical and clinical measurements
Mean (SD) Mean (SD)
BMI (Kg/m2) 1358 26.48 (0.14) 28.84 ± 0.66 1.09 (1.04–1.13) <0.001
Waist circumference, cm 1358 89.47 (0.39) 96.19 ± 1.82 1.03 (1.02–1.05) <0.001
Blood pressure, mm Hg
Systolic 1357 129.08 ± 0.48 138.79 ± 2.42 1.03 (1.02–1.04) <0.001
Diastolic 1359 82.05 ± 0.3 86.32 ± 1.39 1.03 (1.02–1.05) <0.001
Pulse rate, beats/min 1359 68.87 ± 0.28 70.89 ± 0.99 1.02 (0.99–1.04) 0.07
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Table 3 Distribution of CKD according to demographic, socio-economic, behavioural and health-related characteristics of participantsa
in ORISCAV-LUX study, 2007-08, aged 18–69 years (Continued)
Characteristics n No CKD CKDb Crude OR 95% CI P-value
FPG, mg/dl 1330 93.89 ± 0.44 110.43 ± 4.39 1.03 (1.02–1.03) <0.001
HbA1c, % 1330 5.55 ± 0.01 6.02 ± 0.11 2.81 (2.08–3.8) <0.001
Serum total cholesterol, mg/dl 1331 201.35 ± 1.13 196.78 ± 5.51 1.00 (0.99–1.00) 0.31
Serum HDL cholesterol, mg/dl 1331 61.49 ± 0.48 54.51 ± 1.86 0.97 (0.96–0.99) <0.001
Serum LDL cholesterol, mg/dl 1331 124.36 ± 0.98 121.4 ± 4.47 0.998 (0.99–1.00) 0.45
Serum triglycerides, mg/dl 1331 113.07 ± 2.43 162.89 ± 18.81 1.00 (1.00–1.00) <0.001
Serum haemoglobin, mg/dl 1358 14.68 ± 0.037 14.65 ± 0.17 0.98 (0.84–1.15) 0.83
Serum creatinine, mg/dl 1359 0.83 ± 0.004 0.94 ± 0.047 10.45 (3.47–31.45) <0.001
Serum uric acid, mg/dl 1359 5.08 ± 0.038 5.31 ± 0.17 1.12 (0.97–1.31) 0.13
hs-CRP, μg/l 1359 2.65 ± 0.13 3.25 ± 0.44 1.02 (0.98–1.05) 0.26
Serum ALT, mg/dl 1359 25.39 ± 0.45 29.56 ± 1.82 1.01 (1.00–1.02) 0.02
Serum AST, mg/dl 1359 22.54 ± 0.25 23.1 ± 0.91 1.01 (0.98–1.03) 0.56
Serum γGT, mg/dl 1359 32.94 ± 1.22 37.18 ± 3.17 1.00 (0.99–0.01) 0.37
Associated pathologies
N (%) N (%)
Hypertensiond 1358 <0.001
No 816 (64.3) 26 (29.2) 1(Ref.)
Yes 453 (35.7) 63 (70.8) 4.36 (2.72–6.99)
Family history of HTA 1145 0.93
No 645 (60.3) 44 (58.7) 1(Ref.)
Yes 425 (39.7) 31 (41.3) 1.07 (0.66–1.72)
Diabetes mellitusc 1331 <0.001
No 1196 (96.3) 68 (77.4) 1(Ref.)
Yes 46 (3.7) 21 (23.6) 8.03 (4.54–14.21)
Family history of diabetes 1287 0.06
No 938 (78) 58 (69) 1(Ref.)
Yes 265 (22) 26 (31) 1.59 (0.98–2.57)
Obesity 1358 <0.001
BMI <30 Kg/m2 990 (78) 49 (55.1) 1(Ref.)
BMI ≥30 Kg/m2 279 (22) 40 (44.9) 2.9 (1.87–4.49)
Dietary consumption
Mean (SD) Mean (SD)
Salt, mg/day 1270 8.91 ± 0.11 8.79 ± 0.42 0.99 (0.94–1.05) 0.81
Meat, mg/day 1282 109.16 ± 2.44 112.84 ± 8.38 1.00 (0.99–1.00) 0.7
Fruit & vegetables, g/day 1278 556.22 ± 11.47 608.34 ± 45.97 1.00 (1.00–1.00) 0.25
Animal protein, g/day 1267 62.87 ± 0.83 63.74 ± 3.23 1.00 (0.99–1.00) 0.79
FPG fasting plasma glucose, HbA1c glycated Hb, WC waist circumference, ALT Alanine transaminase, AST Aspartate Aminotransferase,
γ-GT Gamma-glutamyl-transpeptidase
Data presented are means ± SE for continuous variables, otherwise numbers (%) for categorical variables
aDifference in the number of cases is related to missing values for several variables
bCKD estimated by MDRD equation
cParticipants were classified as having diabetes when serum glucose was 126 mg/dl or when they reported taking antidiabetic medications
dParticipants were classified as having HT when systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or taking
antihypertensive medications
Alkerwi et al. BMC Nephrology  (2017) 18:358 Page 6 of 10
guidelines. This is the first nationwide study to describe
the epidemiology of CKD in Luxembourg, based on a
standardized definition and staging of renal impairment,
as suggested by the internationally accepted KDOQI
guidelines [19, 22].
Our findings indicate that more than 6% of the general
population in Luxembourg (representing >18,000 adults
nationally) suffered from one of the 5 stages of renal im-
pairment. Moreover, 0.7% (representing >2000 people)
had severe macroalbuminuria (>300 mg/g Cr), and 0.1%
had kidney failure. Normal individuals usually excrete
very small amounts of protein in the urine. Persistently
increased protein excretion is usually a sensitive marker
of kidney damage. These findings flag a neglected public
health issue in Luxembourg, which warrants national
attention and further investigations.
These prevalence estimates were comparable to data
from Lausanne city in Switzerland, where one in 10
adults suffers from CKD, using similar diagnostic criteria
[26]. Recent CKD Burden Consortium data suggests a
substantial variation (from 3.3% to 17.3%) in CKD preva-
lence across Europe [27]. Based on earlier studies, a
South-North gradient has been observed in CKD preva-
lence estimates, being higher in northeastern Italy
(13.2%) [28] and Galician population in Spain (12.7%)
[29] compared with Iceland (age-adjusted prevalence of
low eGFR for adults, aged 35–80 years, was 4.7 and
11.6% for men and women, respectively) [30]. In the
USA, 25 million people (about 12%) are estimated to
have CKD, whereas only <0.2% (<500,000) have kidney
failure treated by dialysis or transplantation [1, 31]. Simi-
lar prevalence estimates have been reported in Australia
[32], and some reports note an increasing prevalence
over time [33, 34]. Although our national CKD estimates
are lower than the worldwide range (8–16%), [7] their
public health burden is worsening with escalating CVD
mortality and comorbidities, presenting substantial
medical expenses.
Thus far, studies on CKD prevalence have been
hampered by selection bias, or inappropriate detection
criteria to define CKD stages [35]. Direct international
comparisons is difficult due to important methodological
differences regarding the setting of the target population,
study design, as well as to the variety of CKD definitions
used across different studies.
There are a number of potential factors that may have
contributed to the relatively high prevalence of CKD
among adults in Luxembourg. Consistent with previous
reports [26], an elevated prevalence of CKD was
observed in hypertensive (70.3%), diabetic (23.1%) and
obese (44%) participants in the ORISCAV-LUX study.
These conditions are highly prevalent in the
Luxembourg population, as supported by our previous
findings from ORISCAV-LUX study population [12].
The likelihood for CKD was significantly and independ-
ently increased by 3-fold and 4-fold in the presence of
hypertension and diabetes, respectively. In addition,
elevated serum triglycerides was substantially associated
with higher odds for CKD. Evidence suggests that hyper-
tension and diabetes are two major causes of kidney
disease [36, 37]. As a complication, high BP may also
develop early during the course of CKD and is associ-
ated with adverse outcomes, in particular, faster loss of
kidney function and development of CVD [19]. In
addition, the risk of CVD, retinopathy, and other
diabetic complications is higher in patients with diabetic
Table 4 Independent demographic, socio-economic, behavioural and health-related correlates to CKD as identified by multivariate
logistic regression; in 1256 participants in the ORISCAV-LUX study, 2007-08, aged 18–69 years
Multivariable Analysis
Covariates Categories Adjusted OR (95% CI) p-value
Gender Male vs female 0.52 (0.28–0.97) 0.041
Educational Level 0.35
Primary v. tertiary 0.70 (0.38–1.29)
Secondary v. tertiary 1.01 (0.53–1.92)
Total MET-hour/week 5 units increase 0.97 (0.95–0.99) 0.032
BMI 1 unit increase 0.95 (0.86–1.05) 0.35
WC 1 cm increase 1.01 (0.97–1.05) 0.71
HDL cholesterol 1 mg/dl increase 0.97 (0.95–0.99) 0.009
Serum triglycerides 1 mg/dl increase 1.002 (1.00–1.004) 0.02
Serum ALT 1 mg/dl increase 0.99 (0.98–1.01) 0.57
Hypertension Hypertensive v. non-hypertensive 3.46 (1.92–6.24) <0.001
Diabetes Diabetic v. non-diabetic subjects 4.45 (2.18–9.07) <0.001
Age groups 50–69 years v. 18–49 years 1.36 (0.79–2.35) 0.26
BMI body mass index, WC waist circumference, HDL cholesterol, high-density lipoprotein cholesterol, ALT Alanine transaminase
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kidney disease than in diabetic patients without kidney
disease [19]. Recently, accumulated evidence indicates
that the adverse outcomes of CKD can be prevented or
delayed through therapeutic interventions during earlier
stages, including blood glucose control in diabetic
subjects, regular BP control, treatment with angiotensin-
converting enzyme inhibitors and angiotensin-receptor
blockers, and dietary protein restriction. Because of the
well-known interactions between CVD, hypertension,
diabetes, and CKD, these findings have important
clinical and public-health implications, in targeting these
“high-risk” population subgroup of the population, who
may benefit most from treatment to reduce progression
and delay the onset of ESRD and cardiovascular
complications [3, 38].
Increased physical activity was independently associ-
ated with lower odd for CKD. This association remained
significant after further adjustment for demographic,
socio-economic, and other lifestyle factors. From a pub-
lic health standpoint, these findings may be interesting.
Only a few population-based studies have reported this
relationship [39, 40]; further prospective studies are
needed to replicate this finding.
Strengths and limitations
This study is has several strong points. Our findings are
based on a large nationwide, population-based sample of
general adults in Luxembourg [12], showed to be com-
parable with the non-participants regarding demo-
graphic and clinical characteristics, hence reducing the
potential selection bias [41]. Data weighting was applied
to provide population-representative prevalence esti-
mates. Kidney function was evaluated according to the
most recent guidelines, based on a combination of eGFR
which provides data on CKD stages, and urinary ACR
which allows identification of 3 levels of microalbumi-
nuria [4]. To estimate GFR, we applied the most widely
used modified MDRD formula in clinical practice and
epidemiological research, which accounts for the
difference in assay methods by using correction factors
[18, 42]. This formula is now being used for direct
reporting of eGFR by our national laboratory in
Luxembourg and other international laboratories to
identify and monitor patients with reduced renal
function [42]. To permit international comparison,
prevalence estimates by CKD-EPI equation were
presented and showed a minor difference. Additionally,
the ORISCAV-LUX survey measured a large set of
potential risk factors for CKD, including demographic,
socio-economic, clinical, biological behavioural and
dietary variables that have been rarely altogether investi-
gated in similar studies.
Potential limitations include factors related to the
cross-sectional design of the study which precludes
inferences regarding causal relationships, single
measures of eGFR and ACR due to unavailability of fur-
ther samples to assess persistence pathology for
≥3 months; in addition to unavailability of data for par-
ticipants older than 69 years, who have highest CKD
prevalence estimates. Other shortcoming points include
potential misclassification of albuminuria due to early-
(not first-) morning sample; some statistically significant
results may not be clinically significant due to low over-
all number of cases (89 with CKD), and extremely low
numbers of person with higher-stage CKD (unstable
estimates) with potential collinearity of variables.
CKD prevalence estimation is central to CKD manage-
ment and prevention planning at the population level
[27] and thereby help estimate the growing burden and
demand for CKD services concomitant with aging popu-
lation. We trust that our findings contribute to filling
gaps on the worldwide atlas examining heterogeneities
in CKD prevalence estimates. Such knowledge may pro-
vide an insight on recommendation to extend screening
to people without diabetes or hypertension.
Conclusions
This is the first evidence-based report on the epidemi-
ology of CKD in Luxembourg, highlighting that early
preventive measures are needed to detect chronic kidney
impairment and to reduce the incidence and mortality
arising from the associated comorbidities. Given the
burden of this public health problem [10], such data
should guide national authorities and contribute to in-
crease the awareness of scientific societies regarding the
benefit of early detection of CKD, particularly in more
susceptible and more disadvantaged groups. Earlier de-
tection and appropriate management of CKD subjects
will reduce cardiovascular events and slow further de-
terioration in renal function in these patients. These
measures altogether could defray costs related to even-
tual ESRD development and higher risk of cardiovascu-
lar events.
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